(Q28367696)

English

Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial (English)

0 references

multiple sclerosis

0 references

chronic progressive multiple sclerosis

1 reference

based on heuristic

inferred from title

John Julian Fung

10

object named as

J J Fung

1 reference

ORCID Public Data File 2021

Muhammad Abu-Elmagd

6

object named as

K Abu-Elmagd

0 references

author name string

B Lemster

1

0 references

L L Huang

2

0 references

W Irish

3

0 references

J Woo

4

0 references

P B Carroll

5

0 references

H R Rilo

7

0 references

N Johnson

8

0 references

R Russell-Hall

9

0 references

language of work or name

0 references

publication date

1994

0 references

0 references

19

0 references

2

0 references

89-98

0 references

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

20 March 2017

Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

20 March 2017

Neurologic complications of FK 506

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

20 March 2017

An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Alternatives to randomized clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Selective loss of a subset of T helper cells in active multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

FK 506 for liver, kidney, and pancreas transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

FK-506--how much potential?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

MS: a CNS and systemic autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Adverse effects associated with the use of FK 506

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Multiple sclerosis: immunological findings and possible implications for therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Immunological aspects of demyelinating diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

29 September 2017

Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

2 June 2018

Deficiency of CD4+CD45R+ T lymphocytes in common variable immunodeficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

2 June 2018

The Influence of FK-506 and Low-Concentration Ciclosporin on Human Lymphocyte Activation Antigen Expression and Blastogenesis: a Flow Cytometric Analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3005253

2 June 2018

A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FK 506 inhibits cytokine gene and adhesion molecule expression in psoriatic skin lesions

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of CD4+ IL-2R alpha+ and CD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (3 months) FK 506 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A highly sensitive method to assay FK-506 levels in plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FK 506: a new therapeutic agent for severe recalcitrant psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/7539635

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/08916939409009536

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28367696&oldid=2065913285"